 Connection
Erin Schenk to Treatment Outcome
This is a "connection" page, showing publications Erin Schenk has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.071 |
|
|
|
-
Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Oct; 31(5):1251-6.
Score: 0.033
-
Sweis RF, Melero I, Davar D, Garralda E, Hamid O, Chen HA, Evans TRJ, Moore KN, Sacco JJ, Thistlethwaite F, Williams A, Blumenschein GR, Callahan MK, Johnson ML, Schenk EL, Wustner J, Stanhope S, Tao K, Marshall S, Lopez J. Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. J Immunother Cancer. 2026 Jul 20; 14(7).
Score: 0.021
-
Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|